FCCC LOGO Faculty Publications
Martin JM , Handorf EA , Kutikov A , Uzzo RG , Bekelman JE , Horwitz EM , Smaldone MC
The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base
Cancer. 2014 Jul 15;120(14) :2114-21
Back to previous list
Abstract
BACKGROUND: Brachytherapy has been shown to be an efficacious and cost-effective treatment among patients with localized prostate cancer. In this study, the authors examined trends in brachytherapy use for localized prostate cancer using a large national cancer registry. METHODS: In the National Cancer Data Base (NCDB), a total of 1,547,941 patients with localized prostate cancer were identified from 1998 through 2010. Excluding patients with lymph node-positive or metastatic disease, the authors examined primary treatment trends focusing on the use of brachytherapy over time. Patients with available data (2004-2009) were stratified by National Comprehensive Cancer Network risk criteria. Controlling for year of diagnosis and demographic, clinical, and pathologic characteristics, multivariate analyses were performed examining the association between patient characteristics and receipt of brachytherapy. RESULTS: In the study cohort, brachytherapy use reached a peak of 16.7% in 2002, and then steadily declined to a low of 8% in 2010. Of the 719,789 patients with available data for risk stratification, 41.1%, 35.3%, and 23.6%, respectively, met low, intermediate, and high National Comprehensive Cancer Network risk criteria. After adjustment, patients of increasing age and those with Medicare insurance were more likely to receive brachytherapy. In contrast, patients with intermediate-risk or high-risk disease, Medicaid insurance, increasing comorbidity count, and increasing year of diagnosis were less likely to receive brachytherapy. CONCLUSIONS: For patients with localized prostate cancer who are treated at National Cancer Data Base institutions, there has been a steady decline in brachytherapy use since 2003. For low-risk patients, the declining use of brachytherapy monotherapy compared with more costly emerging therapies has significant health policy implications.
Notes
1097-0142 Martin, Jeffrey M Handorf, Elizabeth A Kutikov, Alexander Uzzo, Robert G Bekelman, Justin E Horwitz, Eric M Smaldone, Marc C K07-CA163616/CA/NCI NIH HHS/United States P30-CA006927/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural United States Cancer. 2014 Jul 15;120(14):2114-21. doi: 10.1002/cncr.28697. Epub 2014 Apr 15.